PT-141 Reconstitution Calculator
Turn a target dose you already have into the exact injection volume and insulin syringe units for your vial. The math only. It never picks a dose for you.
Most people who search for a PT-141 dosage calculator want a tool that tells them what to inject. This is not that. What number to run, and whether to run it at all, is a decision for a licensed prescriber who knows your history. This tool handles the part that is pure arithmetic: once you already have a target number from your own protocol source, it converts that number into a concentration, a liquid volume in millilitres, and U-100 syringe units.
Enter your own numbers
The target dose starts at zero, because no dose is suggested here. Drag it to the number from your own protocol source and the math below fills in as you set it.
Target number from your protocol source. The slider starts at zero and no dose is proposed for you, so the result stays blank until you drag it to your own figure.
What the evidence and the community report
These are amounts recorded in published studies and label documents, not recommendations. The Who column says whether a figure came from people or animals, and the bracketed Ref number points to the full citation in Sources at the foot of this page.
The largest figures below are intranasal, from a discontinued or compounded nasal formulation, and are not injected amounts, so read the Route column before the number.
A. Approved label doses
B. Amounts administered in published studies
| Amount | Schedule | Route | Who | Ref |
|---|---|---|---|---|
| 1.75 mg | as needed, over 24 weeks | subcutaneous | human, n = 1,267 | [1] |
| 0.75 mg, 1.25 mg and 1.75 mg | as desired, over 12 weeks | subcutaneous | human, n = 327 | [9] |
| 20 mg | single doses on days 1, 4 and 7 | intranasal | human, n = 24 | [10] |
| 0.3 mg to 10 mg, and 4 mg or 6 mg in the erectile dysfunction arm | not stated | subcutaneous | human, men, n not stated | [11] |
| not stated in the abstract | single dose | intranasal | human, n = 18 | [12] |
C. Community reported practice, self-reported and not peer reviewed
The named source earns commissions from linked vendors.
| Amount | Schedule | Route | Who | Ref |
|---|---|---|---|---|
| 1.75 mg, no more than 8 doses per month | at least 45 minutes before activity, no more than one dose per 24 hours | subcutaneous | self-reported | [13] |
| 7.5 mg, 15 mg and 20 mg, never approved | not stated | intranasal | self-reported | [13] |
| 1 to 2 mg per actuation | not stated | intranasal, compounded | self-reported | [13] |
Disclaimer: no figure in these tables is a recommendation, and what to take, if anything at all, is a decision for a licensed prescriber who knows your history.
Two worked math illustrations
These examples show arithmetic and warning behavior only. They are not doses to take.
Example A: 5 mg vial with 2 mL
Math illustration, not a dose to take. The concentration is 5 / 2 = 2.5 mg/mL, or 2500 mcg/mL. A 250 mcg target gives 250 / 2500 = 0.1 mL, which is 10 units on a U-100 syringe. The vial contains 5000 / 250 = 20 illustrative draws.
Example B: impossible target check
Math illustration, not a dose to take. A 20 mg target is larger than the total 5 mg in the example vial. No water volume can produce it, so the vial warning appears and the syringe-capacity advice stays hidden.
What this calculator does, and what it will not do
A reconstitution calculator answers a mechanical question. A vial contains a known amount of peptide, and adding a known water volume fixes the concentration. From there, any target number you enter has one matching liquid volume. The calculator finds that volume by division.
It will not choose the target. A tool that reads your goals and hands back "inject this much" is giving medical advice, and this calculator does not do that. The target number is something you bring to the calculator. If you do not have one from a licensed prescriber or a protocol source you trust, no calculation on this page can supply it.
How the reconstitution calculation works
The calculator first divides the vial amount by the water volume to find concentration. It then divides the target number by that concentration to find millilitres. The U-100 conversion multiplies millilitres by 100.
concentration = vial amount / water volume
liquid volume = target number / concentration
U-100 units = liquid volume in mL x 100
Picking the BAC water volume
The amount of water does not change how much peptide is in the vial. It changes the concentration and the liquid volume for the target number you enter. A 10 mg vial with 1 mL is twice as concentrated as the same vial with 2 mL, so the same target produces half the liquid volume. Use the water volume in your written instructions, then enter it above to see the resulting math.
Reading the insulin syringe
The calculator uses the U-100 conversion:
1 unit = 0.01 mL
100 units = 1 mL = full 1 mL barrel
A result of 0.5 mL is 50 units, and a result of 0.25 mL is 25 units. The calculator shows both formats and checks the result against the selected 0.3 mL, 0.5 mL, or 1.0 mL barrel capacity.
Why the Vyleesi label is not the calculator default
PT-141 has an FDA-approved product, Vyleesi. The pivotal trials and drug review document a specific approved population, and the subgroup analysis documents self-administration with a prefilled autoinjector (PMID: 31599840, PMID: 31893927, PMID: 35230162). That product is not a reconstituted vial. Its label figure therefore does not belong in this calculator as a suggested starting point.
These sources mark the boundary between approved-product facts and vial arithmetic. For information about the compound itself, read the PT-141 compound profile.
Sources
1. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019 Nov;134(5):899-908. PMID: 31599840. DOI: 10.1097/AOG.0000000000003500.
2. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019 Nov;134(5):909-917. PMID: 31599847. DOI: 10.1097/AOG.0000000000003514.
3. Althof S, Derogatis LR, Greenberg S, Clayton AH, Jordan R, Lucas J, et al. Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide. J Sex Med. 2019 Aug;16(8):1226-1235. PMID: 31277966. DOI: 10.1016/j.jsxm.2019.05.012.
4. Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother. 2020 Jul;54(7):684-690. PMID: 31893927. DOI: 10.1177/1060028019899152.
5. Simon JA, Kingsberg SA, Portman D, Jordan R, Lucas J, Sadiq A, et al. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. J Womens Health (Larchmt). 2022 Mar;31(3):391-400. PMID: 35230162. DOI: 10.1089/jwh.2021.0225.
6. Pfaus J, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med. 2007 Nov;4 Suppl 4:269-79. PMID: 17958619. DOI: 10.1111/j.1743-6109.2007.00610.x.
7. Ückert S, Bannowsky A, Albrecht K, Kuczyk MA. Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies. Expert Opin Investig Drugs. 2014 Nov;23(11):1477-83. PMID: 25096243. DOI: 10.1517/13543784.2014.934805.
8. VYLEESI (bremelanotide) injection, Cosette Pharmaceuticals. DailyMed Structured Product Label, section 2.1 Recommended Dosage. DailyMed SPL f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf. Population: premenopausal women with acquired generalized hypoactive sexual desire disorder. Label figures: 1.75 mg subcutaneous, abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity; not more than one dose within 24 hours; more than 8 doses per month is not recommended.
9. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016. PMID: 27181790. Population: premenopausal women with female sexual dysfunctions, n = 327 in the efficacy analysis.
10. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol. Clin Ther. 2017. PMID: 28189361. Population: healthy male and female participants, n = 24, 12 men and 12 women, coadministered with or without oral ethanol 0.6 g/kg. The 20 mg figure is the discontinued intranasal formulation, not an injected amount.
11. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004. PMID: 14999221. Population: healthy male subjects and men with erectile dysfunction reporting inadequate response to sildenafil, n not stated in the abstract. Healthy male subjects received 0.3 mg to 10 mg, with a statistically significant erectile response at doses above 1.0 mg; erectile dysfunction patients received placebo, 4 mg or 6 mg.
12. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141). J Sex Med. 2006. PMID: 16839319. Population: premenopausal women with female sexual arousal disorder, n = 18. A single intranasal dose, amount not stated in the abstract.
13. Peptide Dosing Protocols (Garret Grant), PT-141 Dosing Guide, peptidedosingprotocols.com/protocol/bremelanotide-pt-141, fetched 2026-08-04. Affiliate model: the site does not sell peptides directly but earns commissions from linked vendors. Self-reported, human, self-selected community, not a study population. The 7.5 mg, 15 mg and 20 mg intranasal figures are cited there as historical phase 2 amounts that were never approved; only the 20 mg intranasal figure was independently verified, the 7.5 mg and 15 mg figures were not. Compounded nasal sprays at 1 to 2 mg per actuation are described there as non FDA approved formulations with inconsistent delivery.
Frequently asked questions
Does this calculator choose a PT-141 dose?
No. The target dose slider sits at zero on first load, so no number is put in front of you and the results stay blank until you move it. Drag it to the target figure given by your own licensed prescriber or protocol source. The calculator then handles concentration and draw math only.
How do I enter a target in milligrams instead of micrograms?
Choose mg in the dose unit field, then enter the target number from your own protocol source. The calculator converts that entry to micrograms for its internal arithmetic and keeps the displayed result in millilitres and U-100 syringe units.
How much BAC water do I add to a 10 mg PT-141 vial?
There is no single answer from the calculator because water volume changes concentration, not the total peptide in the vial. A 10 mg vial in 2 mL gives 5 mg/mL. The same vial in 1 mL gives 10 mg/mL, so the same target number produces half the draw volume at the higher concentration. Enter the water volume from your written instructions to see its arithmetic.
Why is Vyleesi different from a reconstituted vial?
The approved product documented in the cited record is a prefilled autoinjector, not a vial the user mixes. This calculator handles arithmetic for the vial and water values you enter. It does not reproduce label instructions or turn the approved product label figure into a default.
What happens if the target is larger than the vial?
No reconstitution volume can produce a target larger than the total peptide in the vial. The calculator shows a red vial warning and suppresses the syringe-capacity advice, because changing the water volume cannot fix an impossible target.
How do I read insulin syringe units?
On a U-100 insulin syringe, 1 unit equals 0.01 mL and 100 units equals 1 mL. The calculator multiplies the volume in millilitres by 100 and shows the result as syringe units. Check that result against the markings and capacity of the syringe you selected.
Is this calculator medical advice?
No. It is harm reduction education. It performs reconstitution arithmetic on numbers you supply. It does not diagnose, does not prescribe, and does not tell you what dose to take. Dose and schedule are a prescriber decision. Always cross-check with your protocol source, supplier instructions, and where possible a qualified clinician.
This is harm reduction education, not medical advice
This calculator is for educational use. It converts a dose you already have into a volume and syringe reading. It does not choose a dose. Peptide protocols vary between individuals and compounds. Always cross-check with your protocol source, supplier instructions, and where possible a qualified clinician.